
According to data from Benzinga Pro, during Q1, Alnylam Pharmaceuticals's (NASDAQ:ALNY) reported sales totaled $213.26 million. Despite a 7.01% increase in earnings, the company posted a loss of $240.34 million. Alnylam Pharmaceuticals collected $258.54 million in revenue during Q4, but reported earnings showed a $258.46 million loss.